Moberg Pharma AB (publ) (MOB) - Net Assets
Based on the latest financial reports, Moberg Pharma AB (publ) (MOB) has net assets worth Skr665.22 Million SEK (≈ $71.59 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr682.26 Million ≈ $73.42 Million USD) and total liabilities (Skr17.04 Million ≈ $1.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MOB tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr665.22 Million |
| % of Total Assets | 97.5% |
| Annual Growth Rate | 24.88% |
| 5-Year Change | 53.26% |
| 10-Year Change | 18.45% |
| Growth Volatility | 2597.21 |
Moberg Pharma AB (publ) - Net Assets Trend (2008–2025)
This chart illustrates how Moberg Pharma AB (publ)'s net assets have evolved over time, based on quarterly financial data. See Moberg Pharma AB (publ) (MOB) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Moberg Pharma AB (publ) (2008–2025)
The table below shows the annual net assets of Moberg Pharma AB (publ) from 2008 to 2025. For live valuation and market cap data, see how much is Moberg Pharma AB (publ) worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr665.22 Million ≈ $71.59 Million |
-3.14% |
| 2024-12-31 | Skr686.82 Million ≈ $73.91 Million |
+12.46% |
| 2023-12-31 | Skr610.73 Million ≈ $65.72 Million |
+14.46% |
| 2022-12-31 | Skr533.58 Million ≈ $57.42 Million |
+22.93% |
| 2021-12-31 | Skr434.05 Million ≈ $46.71 Million |
+9.73% |
| 2020-12-31 | Skr395.58 Million ≈ $42.57 Million |
+274.31% |
| 2019-12-31 | Skr105.68 Million ≈ $11.37 Million |
-82.21% |
| 2018-12-31 | Skr594.02 Million ≈ $63.93 Million |
+7.53% |
| 2017-12-31 | Skr552.41 Million ≈ $59.45 Million |
-1.64% |
| 2016-12-31 | Skr561.62 Million ≈ $60.44 Million |
+59.18% |
| 2015-12-31 | Skr352.82 Million ≈ $37.97 Million |
+16.16% |
| 2014-12-31 | Skr303.75 Million ≈ $32.69 Million |
+50.75% |
| 2013-12-31 | Skr201.49 Million ≈ $21.68 Million |
+13.05% |
| 2012-12-31 | Skr178.23 Million ≈ $19.18 Million |
+132.11% |
| 2011-12-31 | Skr76.79 Million ≈ $8.26 Million |
+11065.80% |
| 2010-12-31 | Skr687.70K ≈ $74.01K |
-97.72% |
| 2009-12-31 | Skr30.21 Million ≈ $3.25 Million |
+98.36% |
| 2008-12-31 | Skr15.23 Million ≈ $1.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Moberg Pharma AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56136331400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr47.00 Million | 7.07% |
| Other Components | Skr1.24 Billion | 186.27% |
| Total Equity | Skr665.22 Million | 100.00% |
Moberg Pharma AB (publ) Competitors by Market Cap
The table below lists competitors of Moberg Pharma AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Space Hellas SA
AT:SPACE
|
$46.75 Million |
|
ZENTEK LTD.
F:ZAY0
|
$46.77 Million |
|
Sinsin Pharmaceutical Co. Ltd
KQ:002800
|
$46.78 Million |
|
NDL Ventures Limited
NSE:NDLVENTURE
|
$46.79 Million |
|
Shalimar Paints Limited
NSE:SHALPAINTS
|
$46.73 Million |
|
Rama Phosphates Limited
NSE:RAMAPHO
|
$46.73 Million |
|
Feerum S.A.
WAR:FEE
|
$46.72 Million |
|
Southern Rubber Industry JSC
VN:CSM
|
$46.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Moberg Pharma AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 686,820,000 to 665,220,000, a change of -21,600,000 (-3.1%).
- Net loss of 27,236,000 reduced equity.
- Share repurchases of 68,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-27.24 Million | -4.09% |
| Share Repurchases | Skr68.00K | -0.01% |
| Other Changes | Skr5.70 Million | +0.86% |
| Total Change | Skr- | -3.14% |
Book Value vs Market Value Analysis
This analysis compares Moberg Pharma AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.17x to 0.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr54.34 | Skr9.24 | x |
| 2009-12-31 | Skr94.72 | Skr9.24 | x |
| 2010-12-31 | Skr0.96 | Skr9.24 | x |
| 2011-12-31 | Skr83.77 | Skr9.24 | x |
| 2012-12-31 | Skr156.22 | Skr9.24 | x |
| 2013-12-31 | Skr152.72 | Skr9.24 | x |
| 2014-12-31 | Skr201.69 | Skr9.24 | x |
| 2015-12-31 | Skr209.41 | Skr9.24 | x |
| 2016-12-31 | Skr330.65 | Skr9.24 | x |
| 2017-12-31 | Skr268.79 | Skr9.24 | x |
| 2018-12-31 | Skr191.45 | Skr9.24 | x |
| 2019-12-31 | Skr6.20 | Skr9.24 | x |
| 2020-12-31 | Skr131.95 | Skr9.24 | x |
| 2021-12-31 | Skr63.43 | Skr9.24 | x |
| 2022-12-31 | Skr46.88 | Skr9.24 | x |
| 2023-12-31 | Skr21.84 | Skr9.24 | x |
| 2024-12-31 | Skr18.15 | Skr9.24 | x |
| 2025-12-31 | Skr14.20 | Skr9.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Moberg Pharma AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -201.18%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.03x
- Recent ROE (-4.09%) is above the historical average (-269.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -232.05% | 0.00% | 0.00x | 1.48x | Skr-36.86 Million |
| 2009 | -80.22% | -1499.35% | 0.05x | 1.17x | Skr-27.26 Million |
| 2010 | -4512.26% | -364.56% | 0.69x | 18.01x | Skr-31.10 Million |
| 2011 | -8.31% | -11.41% | 0.61x | 1.20x | Skr-14.06 Million |
| 2012 | 20.09% | 31.84% | 0.40x | 1.58x | Skr17.99 Million |
| 2013 | -5.64% | -7.22% | 0.58x | 1.35x | Skr-31.51 Million |
| 2014 | 4.04% | 6.13% | 0.56x | 1.18x | Skr-18.11 Million |
| 2015 | 7.24% | 8.94% | 0.72x | 1.13x | Skr-9.75 Million |
| 2016 | 5.82% | 9.77% | 0.27x | 2.19x | Skr-23.49 Million |
| 2017 | 2.02% | 2.54% | 0.36x | 2.21x | Skr-44.08 Million |
| 2018 | 3.34% | 4.52% | 0.35x | 2.11x | Skr-39.56 Million |
| 2019 | 7.53% | 25.82% | 0.24x | 1.24x | Skr-2.61 Million |
| 2020 | -4.91% | -56.53% | 0.07x | 1.24x | Skr-57.81 Million |
| 2021 | -3.74% | -7.74% | 0.47x | 1.04x | Skr-59.63 Million |
| 2022 | -2.94% | -7589.37% | 0.00x | 1.06x | Skr-69.07 Million |
| 2023 | -3.45% | -7.72% | 0.43x | 1.04x | Skr-82.17 Million |
| 2024 | -37.14% | -2600.25% | 0.01x | 1.03x | Skr-323.79 Million |
| 2025 | -4.09% | -201.18% | 0.02x | 1.03x | Skr-93.76 Million |
Industry Comparison
This section compares Moberg Pharma AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $255,406,623
- Average return on equity (ROE) among peers: -188.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Moberg Pharma AB (publ) (MOB) | Skr665.22 Million | -232.05% | 0.03x | $46.74 Million |
| BioGaia AB (publ) (BIOG-B) | $132.42 Million | 27.28% | 0.17x | $1.25 Billion |
| Enzymatica publ AB (ENZY) | $124.97 Million | -36.32% | 0.26x | $65.83 Million |
| Enorama Pharma AB (ERMA) | $1.78 Million | -1345.02% | 22.02x | $2.69 Million |
| Gabather AB (publ) (GABA) | $33.19 Million | -23.79% | 0.05x | $2.48 Million |
| Klaria Pharma Holding AB (KLAR) | $69.42 Million | -77.12% | 0.70x | $20.99 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $77.75 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $68.77 Million | -21.33% | 0.26x | $6.28 Million |
| Orexo AB (ORX) | $58.90 Million | -217.83% | 12.35x | $79.38 Million |
| Swedish Orphan Biovitrum AB (publ) (SOBI) | $1.71 Billion | 10.32% | 0.60x | $16.38 Billion |
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.